Neoplasias y trasplante renal
Palabras clave:
neoplasias renales; trasplante renal; tumores postrasplante; virus oncogénicos; screening de neoplasias; agentes antineoplásicos
Resumen
El trasplante renal se ha consolidado como la terapia sustitutiva de elección para pacientes con insuficiencia renal crónica, con aumento de la sobrevida y mejoría de la calidad de vida. Estos pacientes presentan una elevada incidencia de procesos oncológicos respecto de la población general, cuya diferencia varía según la neoplasia considerada. Por otra parte, los procesos oncológicos tienden a ser más agresivos y manifestarse a edades más tempranas. El desarrollo de métodos de screening, el estudio de factores de riesgo, el ajuste de medicación inmunosupresora, la implementación de estudios complementarios sobre los efectos de la terapéutica oncológica sobre el implante son algunos de los puntos a considerar.
Citas
1) Cheung CY, Lam MF, Chu KH, Chow KM, Tsang KY, Yuen SK, et al. Malignancies after kidney transplantation: Hong Kong renal registry. Am J Transplant. 2012;12(11):3039-46.
2) Collett D, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant. 2010;10(8):1889-96.
3) Engels EA, Pfeiffer RM, Fraumeni JF Jr, Kasiske BL, Israni AK, Snyder JJ, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306(17):1891-901.
4) Krynitz B, Edgren G, Lindelöf B, Baecklund E, Brattström C, Wilczek H, et al. Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008, a Swedish population-based study. Int J Cancer. 2013;132(6):1429-38.
5) Kyllönen L, Salmela K, Pukkala E. Cancer incidence in a kidney-transplanted population. Transpl Int. 2000;13(Suppl. 1):S394-8.
6) Li WH, Chen YJ, Tseng WC, Lin MW, Chen TJ, Chu SY, et al. Malignancies after renal transplantation in Taiwan: a nationwide population-based study. Nephrol Dial Transplant. 2012;27(2):833-9.
7) Piselli P, Serraino D, Segoloni GP, Sandrini S, Piredda GB, Scolari MP, et al. Risk of de novo cancers after transplantation: results from a cohort of 7217 kidney transplant recipients, Italy 1997-2009. Eur J Cancer. 2013;49(2):336-44.
8) Stewart JH, Vajdic CM, van Leeuwen MT, Amin J, Webster AC, Chapman JR, et al. The pattern of excess cancer in dialysis and transplantation. Nephrol Dial Transplant. 2009;24(10):3225-31.
9) Tessari G, Naldi L, Boschiero L, Minetti E, Sandrini S, Nacchia F, et al. Incidence of primary and second cancers in renal transplant recipients: a multicenter cohort study. Am J Transplant. 2013;13(1):214-21.
10) Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, et al. Cancer incidence before and after kidney transplantation. JAMA. 2006;296(23):2823-31.
11) Villeneuve PJ, Schaubel DE, Fenton SS, Shepherd FA, Jiang Y, Mao Y. Cancer incidence among Canadian kidney transplant recipients. Am J Transplant. 2007;7(4):941-8.
12) Yanik EL, Clarke CA, Snyder JJ, Pfeiffer RM, Engels EA. Variation in cancer incidence among patients with ESRD during kidney function and nonfunction intervals. J Am Soc Nephrol. 2016;27(5):1495-504.
13) Asch WS, Bia MJ. Oncologic issues and kidney transplantation: a review of frequency, mortality, and screening. Adv Chronic Kidney Dis. 2014;21(1):106-13.
14) Dantal J, Hourmant M, Cantarovich D, Giral M, Blancho G, Dreno B, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet. 1998;351(9103):623-8.
15) Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 1999;397(6719):530-4.
16) Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation. 2005;80(9):1233-43.
17) Cheung CY, Tang SCW. An update on cancer after kidney transplantation. Nephrol Dial Transplant. 2019;34(6):914-20.
18) Wong G, Hayen A, Chapman JR, Webster AC, Wang JJ, Mitchell P, et al. Association of CKD and cancer risk in older people. J Am Soc Nephrol. 2009;20(6):1341-50.
19) Cheung CY, Ma MKM, Chak WL, Tang SCW. Cancer risk in patients with diabetic nephropathy: A retrospective cohort study in Hong Kong. Medicine (Baltimore). 2017;96(38):e8077.
20) Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet. 1999;354(9173):93-9.
21) Au E, Wong G, Chapman JR. Cancer in kidney transplant recipients. Nat Rev Nephrol. 2018;14(8):508-20.
22) Farrugia D, Mahboob S, Cheshire J, Begaj I, Khosla S, Ray D, et al. Malignancy-related mortality following kidney transplantation is common. Kidney Int. 2014;85(6):1395-403.
23) Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1-10.
24) Webster AC, Craig JC, Simpson JM, Jones MP, Chapman JR. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. Am J Transplant. 2007;7(9):2140-51.
25) Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4(6):905-13.
26) Myron Kauffman H, McBride MA, Cherikh WS, Spain PC, Marks WH, Roza AM. Transplant tumor registry: donor related malignancies. Transplantation. 2002;74(3):358-62.
27) Desai R, Collett D, Watson CJ, Johnson P, Evans T, Neuberger J. Cancer transmission from organ donors-unavoidable but low risk. Transplantation. 2012;94(12):1200-7.
28) Xiao D, Craig JC, Chapman JR, Dominguez-Gil B, Tong A, Wong G. Donor cancer transmission in kidney transplantation: a systematic review. Am J Transplant. 2013;13(10):2645-52.
29) Lentine KL, Kasiske BL, Levey AS, Adams PL, Alberú J, Bakr MA, et al. KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors. Transplantation. 2017;101(8S Suppl 1):S1-S109.
30) Brook NR, Gibbons N, Johnson DW, Nicol DL. Outcomes of transplants from patients with small renal tumours, live unrelated donors and dialysis wait-listed patients. Transpl Int. 2010;23(5):476-83.
31) Watson CJ, Roberts R, Wright KA, Greenberg DC, Rous BA, Brown CH, et al. How safe is it to transplant organs from deceased donors with primary intracranial malignancy? An analysis of UK Registry data. Am J Transplant. 2010;10(6):1437-44.
32) Chui AK, Herbertt K, Wang LS, Kyd G, Hodgeman G, Verran DJ, et al. Risk of tumor transmission in transplantation from donors with primary brain tumors: an Australian and New Zealand registry report. Transplant Proc. 1999;31(1-2):1266-7.
33) Acuna SA, Huang JW, Dossa F, Shah PS, Kim SJ, Baxter NN. Cancer recurrence after solid organ transplantation: A systematic review and meta-analysis. Transplant Rev (Orlando). 2017;31(4):240-8.
34) Chapman JR, Sheil AG, Disney AP. Recurrence of cancer after renal transplantation. Transplant Proc. 2001;33(1-2):1830-1.
35) Viecelli AK, Lim WH, Macaskill P, Chapman JR, Craig JC, Clayton P, et al. Cancer-specific and all-cause mortality in kidney transplant recipients with and without previous cancer. Transplantation. 2015;99(12):2586-92.
36) Batabyal P, Chapman JR, Wong G, Craig JC, Tong A. Clinical practice guidelines on wait-listing for kidney transplantation: consistent and equitable? Transplantation. 2012;94(7):703-13.
37) Campbell S, Pilmore H, Gracey D, Mulley W, Russell C, McTaggart S. KHA-CARI Guideline: recipient assessment for transplantation. Nephrology (Carlton). 2013;18(6):455-62.
38) European Renal Best Practice Transplantation Guideline Development Group. ERBP Guideline on the management and evaluation of the kidney donor and recipient. Nephrol Dial Transplant. 2013;28(Suppl. 2):ii1-71.
39) Kälble T, Lucan M, Nicita G, Sells R, Burgos Revilla FJ, Wiesel M, et al. EAU guidelines on renal transplantation. Eur Urol. 2005;47(2):156-66.
40) Kasiske BL, Cangro CB, Hariharan S, Hricik DE, Kerman RH, Roth D, et al. The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant. 2001;1(Suppl. 2):3-95.
41) Knoll G, Cockfield S, Blydt-Hansen T, Baran D, Kiberd B, Landsberg D, et al. Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation. CMAJ. 2005;173(10):S1-25.
42) Segall L, Nistor I, Pascual J, Mucsi I, Guirado L, Higgins R, et al. Criteria for and appropriateness of renal transplantation in elderly patients with end-stage renal disease: a literature review and position statement on behalf of the European Renal Association-European Dialysis and Transplant Association Descartes Working Group and European Renal Best Practice. Transplantation. 2016;100(10):e55-65.
43) Lin JS, Piper MA, Perdue LA, Rutter CM, Webber EM, O'Connor E, et al. Screening for colorectal cancer: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016;315(23):2576-94.
44) Nelson HD, Fu R, Cantor A, Pappas M, Daeges M, Humphrey L. Effectiveness of breast cancer screening: systematic review and meta-analysis to update the 2009 U.S. preventive services task force recommendation. Ann Intern Med. 2016;164(4):244-55.
45) Cristina Villaamil Lepori E. Hidroarsenicismo crónico regional endémico en Argentina. Acta Bioquím Clín Latinoam. 2015;49(1):83-104.
46) Wong G, Howard K, Craig JC, Chapman JR. Cost-effectiveness of colorectal cancer screening in renal transplant recipients. Transplantation. 2008;85(4):532-41.
47) Wong G, Howard K, Webster A, Chapman JR, Craig JC. The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients. Transplantation. 2009;87(7):1078-91.
48) Acuna SA, Huang JW, Scott AL, Micic S, Daly C, Brezden-Masley C, et al. Cancer Screening Recommendations for Solid Organ Transplant Recipients: A Systematic Review of Clinical Practice Guidelines. Am J Transplant. 2017;17(1):103-14.
49) Janus N, Launay-Vacher V, Byloos E, Machiels JP, Duck L, Kerger J, et al. Cancer and renal insufficiency results of the BIRMA study. Br J Cancer. 2010;103(12):1815-21.
50) Canter D, Kutikov A, Sirohi M, Street R, Viterbo R, Chen DY, et al. Prevalence of baseline chronic kidney disease in patients presenting with solid renal tumors. Urology. 2011;77(4):781-5.
51) Nakamura Y, Tsuchiya K, Nitta K, Ando M. Prevalence of anemia and chronic kidney disease in cancer patients: clinical significance for 1-year mortality. Nihon Jinzo Gakkai Shi. 2011;53(1):38-45.
52) Reshef R, Vardhanabhuti S, Luskin MR, Heitjan DF, Hadjiliadis D, Goral S, et al. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder. Am J Transplant. 2011;11(2):336-47.
53) Hope CM, Krige AJ, Barratt A, Carroll RP. Reductions in immunosuppression after haematological or solid organ cancer diagnosis in kidney transplant recipients. Transpl Int. 2015;28(11):1332-5.
54) Chapman JR, Webster AC, Wong G. Cancer in the transplant recipient. Cold Spring Harb Perspect Med. 2013;3(7):a015677.
55) Nichols LA, Adang LA, Kedes DH. Rapamycin blocks production of KSHV/HHV8: insights into the anti-tumor activity of an immunosuppressant drug. PLoS One. 2011;6(1):e14535.
56) Basu G, Mohapatra A, Manipadam MT, Mani SE, John GT. Leflunomide with low-dose everolimus for treatment of Kaposi's sarcoma in a renal allograft recipient. Nephrol Dial Transplant. 2011;26(10):3412-5.
57) Yaich S, Charfeddine K, Zaghdane S, El Aoud N, Jarraya F, Kharrat M, et al. Sirolimus for the treatment of Kaposi sarcoma after renal transplantation: a series of 10 cases. Transplant Proc. 2012;44(9):2824-6.
58) Cullis B, D'Souza R, McCullagh P, Harries S, Nicholls A, Lee R, et al. Sirolimus-induced remission of posttransplantation lymphoproliferative disorder. Am J Kidney Dis. 2006;47(5):e67-72.
59) Boratyńska M, Watorek E, Smolska D, Patrzałek D, Klinger M. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies. Transplant Proc. 2007;39(9):2736-9.
60) Lai HC, Lin JF, Hwang TIS, Liu YF, Yang AH, Wu CK. Programmed cell death 1 (PD-1) inhibitors in renal transplant patients with advanced cancer: a double-edged sword? Int J Mol Sci. 2019;20(9):e2194.
61) Rousseau B, Guillemin A, Duvoux C, Neuzillet C, Tlemsani C, Compagnon P, et al. Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinoma. Int J Cancer. 2019;144(4):886-96.
62) de Francisco ALM, Macía M, Alonso F, García P, Gutierrez E, Quintana LF, et al. Onco-Nefrología: cáncer, quimioterapia y riñón. Nefrología. 2019;39(5):455-562.
63) Edeani A, Cohen EP. Chapter 10: Radiation Nephropathy [Internet]. En: Online Curricula: Onco-Nephrology, Mark A. Perazella (ed.). American Society of Nephrology: 2016. Disponible en: https://www.asn-online.org/education/distancelearning/curricula/onco/Chapter10.pdf (Consulta: 10/06/2019).
64) Jhaveri KD, Rosner MH. Chimeric antigen receptor T cell therapy and the kidney: what the nephrologist needs to know. Clin J Am Soc Nephrol. 2018;13(5):796-8.
65) Kougias P, Sharath S, Barshes NR, Lowery B, Garcia A, Pak T, et al. Impact of cumulative intravascular contrast exposure on renal function in patients with occlusive and aneurysmal vascular disease. J Vasc Surg. 2014;59(6):1644-50.
66) Hong SI, Ahn S, Lee YS, Kim WY, Lim KS, Lee JH, et al. Contrast-induced nephropathy in patients with active cancer undergoing contrast-enhanced computed tomography. Support Care Cancer. 2016;24(3):1011-7.
67) Kidney Disease Improving Global Outcomes Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012;2(1)1-138.
68) Sharma A, Mucino MJ, Ronco C. Renal functional reserve and renal recovery after acute kidney injury. Nephron Clin Pract. 2014;127(1-4):94-100.
69) Estados Unidos. National Cancer Institute, Division of Cancer Control and Population Sciences. Surveillance, Epidemiology and End Results Program (SEER) [Internet]. Disponible en: https://seer.cancer.gov/ (Consulta: 10/06/2019).
70) Australian and New Zealand Dialysis and Transplant Registry (ANZDATA) [Internet]. Disponible en: http://www.anzdata.org.au/v1/index.html (Consulta: 10/06/2019).
71) Israel Penn International Transplant Tumor Registry (IPITTR) [Internet]. Disponible en: https://ipittr.uc.edu/ (Consulta: 10/06/2019).
72) Italian National Transplant Centre. The Vigilance and Suveillance Chain for Medical Products of Human Origin. A Notify Guide, 2018 [Internet]. Disponible en: https://www.notifylibrary.org/content/13-vigilance-and-surveillance-chain-medical-products-human-origin-notify-guide-0 (Consulta: 10/06/2019).
73) Registro Argentino de Tumores en Trasplante [Internet]. Disponible en https://docs.google.com/forms/d/e/1FAIpQLSeRtr8gKqi-_VhiPLq0BPg5-bGFIjsvrRccUBmvdcBOtOv7yg/viewform (Consulta: 10/06/2019).
2) Collett D, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit. Am J Transplant. 2010;10(8):1889-96.
3) Engels EA, Pfeiffer RM, Fraumeni JF Jr, Kasiske BL, Israni AK, Snyder JJ, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306(17):1891-901.
4) Krynitz B, Edgren G, Lindelöf B, Baecklund E, Brattström C, Wilczek H, et al. Risk of skin cancer and other malignancies in kidney, liver, heart and lung transplant recipients 1970 to 2008, a Swedish population-based study. Int J Cancer. 2013;132(6):1429-38.
5) Kyllönen L, Salmela K, Pukkala E. Cancer incidence in a kidney-transplanted population. Transpl Int. 2000;13(Suppl. 1):S394-8.
6) Li WH, Chen YJ, Tseng WC, Lin MW, Chen TJ, Chu SY, et al. Malignancies after renal transplantation in Taiwan: a nationwide population-based study. Nephrol Dial Transplant. 2012;27(2):833-9.
7) Piselli P, Serraino D, Segoloni GP, Sandrini S, Piredda GB, Scolari MP, et al. Risk of de novo cancers after transplantation: results from a cohort of 7217 kidney transplant recipients, Italy 1997-2009. Eur J Cancer. 2013;49(2):336-44.
8) Stewart JH, Vajdic CM, van Leeuwen MT, Amin J, Webster AC, Chapman JR, et al. The pattern of excess cancer in dialysis and transplantation. Nephrol Dial Transplant. 2009;24(10):3225-31.
9) Tessari G, Naldi L, Boschiero L, Minetti E, Sandrini S, Nacchia F, et al. Incidence of primary and second cancers in renal transplant recipients: a multicenter cohort study. Am J Transplant. 2013;13(1):214-21.
10) Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, et al. Cancer incidence before and after kidney transplantation. JAMA. 2006;296(23):2823-31.
11) Villeneuve PJ, Schaubel DE, Fenton SS, Shepherd FA, Jiang Y, Mao Y. Cancer incidence among Canadian kidney transplant recipients. Am J Transplant. 2007;7(4):941-8.
12) Yanik EL, Clarke CA, Snyder JJ, Pfeiffer RM, Engels EA. Variation in cancer incidence among patients with ESRD during kidney function and nonfunction intervals. J Am Soc Nephrol. 2016;27(5):1495-504.
13) Asch WS, Bia MJ. Oncologic issues and kidney transplantation: a review of frequency, mortality, and screening. Adv Chronic Kidney Dis. 2014;21(1):106-13.
14) Dantal J, Hourmant M, Cantarovich D, Giral M, Blancho G, Dreno B, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet. 1998;351(9103):623-8.
15) Hojo M, Morimoto T, Maluccio M, Asano T, Morimoto K, Lagman M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 1999;397(6719):530-4.
16) Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation. 2005;80(9):1233-43.
17) Cheung CY, Tang SCW. An update on cancer after kidney transplantation. Nephrol Dial Transplant. 2019;34(6):914-20.
18) Wong G, Hayen A, Chapman JR, Webster AC, Wang JJ, Mitchell P, et al. Association of CKD and cancer risk in older people. J Am Soc Nephrol. 2009;20(6):1341-50.
19) Cheung CY, Ma MKM, Chak WL, Tang SCW. Cancer risk in patients with diabetic nephropathy: A retrospective cohort study in Hong Kong. Medicine (Baltimore). 2017;96(38):e8077.
20) Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet. 1999;354(9173):93-9.
21) Au E, Wong G, Chapman JR. Cancer in kidney transplant recipients. Nat Rev Nephrol. 2018;14(8):508-20.
22) Farrugia D, Mahboob S, Cheshire J, Begaj I, Khosla S, Ray D, et al. Malignancy-related mortality following kidney transplantation is common. Kidney Int. 2014;85(6):1395-403.
23) Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39(1):1-10.
24) Webster AC, Craig JC, Simpson JM, Jones MP, Chapman JR. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: a cohort study of 15,183 recipients. Am J Transplant. 2007;7(9):2140-51.
25) Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4(6):905-13.
26) Myron Kauffman H, McBride MA, Cherikh WS, Spain PC, Marks WH, Roza AM. Transplant tumor registry: donor related malignancies. Transplantation. 2002;74(3):358-62.
27) Desai R, Collett D, Watson CJ, Johnson P, Evans T, Neuberger J. Cancer transmission from organ donors-unavoidable but low risk. Transplantation. 2012;94(12):1200-7.
28) Xiao D, Craig JC, Chapman JR, Dominguez-Gil B, Tong A, Wong G. Donor cancer transmission in kidney transplantation: a systematic review. Am J Transplant. 2013;13(10):2645-52.
29) Lentine KL, Kasiske BL, Levey AS, Adams PL, Alberú J, Bakr MA, et al. KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors. Transplantation. 2017;101(8S Suppl 1):S1-S109.
30) Brook NR, Gibbons N, Johnson DW, Nicol DL. Outcomes of transplants from patients with small renal tumours, live unrelated donors and dialysis wait-listed patients. Transpl Int. 2010;23(5):476-83.
31) Watson CJ, Roberts R, Wright KA, Greenberg DC, Rous BA, Brown CH, et al. How safe is it to transplant organs from deceased donors with primary intracranial malignancy? An analysis of UK Registry data. Am J Transplant. 2010;10(6):1437-44.
32) Chui AK, Herbertt K, Wang LS, Kyd G, Hodgeman G, Verran DJ, et al. Risk of tumor transmission in transplantation from donors with primary brain tumors: an Australian and New Zealand registry report. Transplant Proc. 1999;31(1-2):1266-7.
33) Acuna SA, Huang JW, Dossa F, Shah PS, Kim SJ, Baxter NN. Cancer recurrence after solid organ transplantation: A systematic review and meta-analysis. Transplant Rev (Orlando). 2017;31(4):240-8.
34) Chapman JR, Sheil AG, Disney AP. Recurrence of cancer after renal transplantation. Transplant Proc. 2001;33(1-2):1830-1.
35) Viecelli AK, Lim WH, Macaskill P, Chapman JR, Craig JC, Clayton P, et al. Cancer-specific and all-cause mortality in kidney transplant recipients with and without previous cancer. Transplantation. 2015;99(12):2586-92.
36) Batabyal P, Chapman JR, Wong G, Craig JC, Tong A. Clinical practice guidelines on wait-listing for kidney transplantation: consistent and equitable? Transplantation. 2012;94(7):703-13.
37) Campbell S, Pilmore H, Gracey D, Mulley W, Russell C, McTaggart S. KHA-CARI Guideline: recipient assessment for transplantation. Nephrology (Carlton). 2013;18(6):455-62.
38) European Renal Best Practice Transplantation Guideline Development Group. ERBP Guideline on the management and evaluation of the kidney donor and recipient. Nephrol Dial Transplant. 2013;28(Suppl. 2):ii1-71.
39) Kälble T, Lucan M, Nicita G, Sells R, Burgos Revilla FJ, Wiesel M, et al. EAU guidelines on renal transplantation. Eur Urol. 2005;47(2):156-66.
40) Kasiske BL, Cangro CB, Hariharan S, Hricik DE, Kerman RH, Roth D, et al. The evaluation of renal transplantation candidates: clinical practice guidelines. Am J Transplant. 2001;1(Suppl. 2):3-95.
41) Knoll G, Cockfield S, Blydt-Hansen T, Baran D, Kiberd B, Landsberg D, et al. Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation. CMAJ. 2005;173(10):S1-25.
42) Segall L, Nistor I, Pascual J, Mucsi I, Guirado L, Higgins R, et al. Criteria for and appropriateness of renal transplantation in elderly patients with end-stage renal disease: a literature review and position statement on behalf of the European Renal Association-European Dialysis and Transplant Association Descartes Working Group and European Renal Best Practice. Transplantation. 2016;100(10):e55-65.
43) Lin JS, Piper MA, Perdue LA, Rutter CM, Webber EM, O'Connor E, et al. Screening for colorectal cancer: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2016;315(23):2576-94.
44) Nelson HD, Fu R, Cantor A, Pappas M, Daeges M, Humphrey L. Effectiveness of breast cancer screening: systematic review and meta-analysis to update the 2009 U.S. preventive services task force recommendation. Ann Intern Med. 2016;164(4):244-55.
45) Cristina Villaamil Lepori E. Hidroarsenicismo crónico regional endémico en Argentina. Acta Bioquím Clín Latinoam. 2015;49(1):83-104.
46) Wong G, Howard K, Craig JC, Chapman JR. Cost-effectiveness of colorectal cancer screening in renal transplant recipients. Transplantation. 2008;85(4):532-41.
47) Wong G, Howard K, Webster A, Chapman JR, Craig JC. The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients. Transplantation. 2009;87(7):1078-91.
48) Acuna SA, Huang JW, Scott AL, Micic S, Daly C, Brezden-Masley C, et al. Cancer Screening Recommendations for Solid Organ Transplant Recipients: A Systematic Review of Clinical Practice Guidelines. Am J Transplant. 2017;17(1):103-14.
49) Janus N, Launay-Vacher V, Byloos E, Machiels JP, Duck L, Kerger J, et al. Cancer and renal insufficiency results of the BIRMA study. Br J Cancer. 2010;103(12):1815-21.
50) Canter D, Kutikov A, Sirohi M, Street R, Viterbo R, Chen DY, et al. Prevalence of baseline chronic kidney disease in patients presenting with solid renal tumors. Urology. 2011;77(4):781-5.
51) Nakamura Y, Tsuchiya K, Nitta K, Ando M. Prevalence of anemia and chronic kidney disease in cancer patients: clinical significance for 1-year mortality. Nihon Jinzo Gakkai Shi. 2011;53(1):38-45.
52) Reshef R, Vardhanabhuti S, Luskin MR, Heitjan DF, Hadjiliadis D, Goral S, et al. Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder. Am J Transplant. 2011;11(2):336-47.
53) Hope CM, Krige AJ, Barratt A, Carroll RP. Reductions in immunosuppression after haematological or solid organ cancer diagnosis in kidney transplant recipients. Transpl Int. 2015;28(11):1332-5.
54) Chapman JR, Webster AC, Wong G. Cancer in the transplant recipient. Cold Spring Harb Perspect Med. 2013;3(7):a015677.
55) Nichols LA, Adang LA, Kedes DH. Rapamycin blocks production of KSHV/HHV8: insights into the anti-tumor activity of an immunosuppressant drug. PLoS One. 2011;6(1):e14535.
56) Basu G, Mohapatra A, Manipadam MT, Mani SE, John GT. Leflunomide with low-dose everolimus for treatment of Kaposi's sarcoma in a renal allograft recipient. Nephrol Dial Transplant. 2011;26(10):3412-5.
57) Yaich S, Charfeddine K, Zaghdane S, El Aoud N, Jarraya F, Kharrat M, et al. Sirolimus for the treatment of Kaposi sarcoma after renal transplantation: a series of 10 cases. Transplant Proc. 2012;44(9):2824-6.
58) Cullis B, D'Souza R, McCullagh P, Harries S, Nicholls A, Lee R, et al. Sirolimus-induced remission of posttransplantation lymphoproliferative disorder. Am J Kidney Dis. 2006;47(5):e67-72.
59) Boratyńska M, Watorek E, Smolska D, Patrzałek D, Klinger M. Anticancer effect of sirolimus in renal allograft recipients with de novo malignancies. Transplant Proc. 2007;39(9):2736-9.
60) Lai HC, Lin JF, Hwang TIS, Liu YF, Yang AH, Wu CK. Programmed cell death 1 (PD-1) inhibitors in renal transplant patients with advanced cancer: a double-edged sword? Int J Mol Sci. 2019;20(9):e2194.
61) Rousseau B, Guillemin A, Duvoux C, Neuzillet C, Tlemsani C, Compagnon P, et al. Optimal oncologic management and mTOR inhibitor introduction are safe and improve survival in kidney and liver allograft recipients with de novo carcinoma. Int J Cancer. 2019;144(4):886-96.
62) de Francisco ALM, Macía M, Alonso F, García P, Gutierrez E, Quintana LF, et al. Onco-Nefrología: cáncer, quimioterapia y riñón. Nefrología. 2019;39(5):455-562.
63) Edeani A, Cohen EP. Chapter 10: Radiation Nephropathy [Internet]. En: Online Curricula: Onco-Nephrology, Mark A. Perazella (ed.). American Society of Nephrology: 2016. Disponible en: https://www.asn-online.org/education/distancelearning/curricula/onco/Chapter10.pdf (Consulta: 10/06/2019).
64) Jhaveri KD, Rosner MH. Chimeric antigen receptor T cell therapy and the kidney: what the nephrologist needs to know. Clin J Am Soc Nephrol. 2018;13(5):796-8.
65) Kougias P, Sharath S, Barshes NR, Lowery B, Garcia A, Pak T, et al. Impact of cumulative intravascular contrast exposure on renal function in patients with occlusive and aneurysmal vascular disease. J Vasc Surg. 2014;59(6):1644-50.
66) Hong SI, Ahn S, Lee YS, Kim WY, Lim KS, Lee JH, et al. Contrast-induced nephropathy in patients with active cancer undergoing contrast-enhanced computed tomography. Support Care Cancer. 2016;24(3):1011-7.
67) Kidney Disease Improving Global Outcomes Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012;2(1)1-138.
68) Sharma A, Mucino MJ, Ronco C. Renal functional reserve and renal recovery after acute kidney injury. Nephron Clin Pract. 2014;127(1-4):94-100.
69) Estados Unidos. National Cancer Institute, Division of Cancer Control and Population Sciences. Surveillance, Epidemiology and End Results Program (SEER) [Internet]. Disponible en: https://seer.cancer.gov/ (Consulta: 10/06/2019).
70) Australian and New Zealand Dialysis and Transplant Registry (ANZDATA) [Internet]. Disponible en: http://www.anzdata.org.au/v1/index.html (Consulta: 10/06/2019).
71) Israel Penn International Transplant Tumor Registry (IPITTR) [Internet]. Disponible en: https://ipittr.uc.edu/ (Consulta: 10/06/2019).
72) Italian National Transplant Centre. The Vigilance and Suveillance Chain for Medical Products of Human Origin. A Notify Guide, 2018 [Internet]. Disponible en: https://www.notifylibrary.org/content/13-vigilance-and-surveillance-chain-medical-products-human-origin-notify-guide-0 (Consulta: 10/06/2019).
73) Registro Argentino de Tumores en Trasplante [Internet]. Disponible en https://docs.google.com/forms/d/e/1FAIpQLSeRtr8gKqi-_VhiPLq0BPg5-bGFIjsvrRccUBmvdcBOtOv7yg/viewform (Consulta: 10/06/2019).
Publicado
2020-09-14
Cómo citar
1.
Taylor MF. Neoplasias y trasplante renal. Rev Nefrol Dial Traspl. [Internet]. 14 de septiembre de 2020 [citado 22 de diciembre de 2024];40(2):161-7. Disponible en: http://revistarenal.org.ar/index.php/rndt/article/view/526
Sección
Artículo de Revisión
Derechos de autor 2020 Revista de Nefrología, Diálisis y Trasplante
Esta obra está bajo licencia internacional Creative Commons Reconocimiento-NoComercial-CompartirIgual 4.0.
